| CIPLA PRODUCT |
ACTIVE |
STRENGTHS |
ORIGINATOR |
SIZE OF
ORIGINATOR |
MAIN INDICATION |
PRIVATE SECTOR
MARKET SIZE
RAND VALUE
[1USD = R 8.00] |
MARKET |
CRITICAL SUCCESS FACTORS |
| |
|
|
|
|
|
|
|
|
| IMPORTANT REGISTRATIONS 04/2008 |
|
|
|
|
|
|
|
| Lexamil |
Escitalopram |
5/10/20 mg |
Cipralex ® |
R 100 million |
Depression |
R 264 million |
SSRI's |
1) First generic to market
2) Originator is fifth leading product in South Africa by value |
| Cipla-Perindopril |
Perindopril Erbumine |
4mg |
Coversyl ® |
R 100 million |
Hypertension & Congestive Heart Failure |
R 195,127 million |
ACE Inhibitor Anti-hypertensive Agent |
1) Locally, perindopril is the second biggest selling ACE inhibitor with a market size
close to R100 million per annum
2) We anticipate to not only rely on generic substitution, but we expect to grow the
overall perindopril market due to Cipla-Perindopril's competitive price |
| Uromax |
Tamsulosin |
0.4mg |
Flomax ® |
R12.3 million |
Benign Prostatic Hyperplasia (BPH) |
R28.7 million |
Alpha blocker |
1) First line drug for treatment of BPH
2) Second generic on market |
| Foratec HFA |
Formoterol Fumarate |
12 µg |
Originator first to market |
First to market |
COPD & Asthma |
R15,4 million |
Bronchodilators |
1) First Formoterol inhaler to market 2) Quick onset of action vs opposition molecules 3) Indications for COPD & Asthma 4) COPD alone was responsible for 2.3% of all deaths in 2000, so a
huge market |
| |
|
|
|
|
|
|
|
|
| IMPORTANT REGISTRATIONS 02/2008 |
|
|
|
|
|
|
|
| Cipla-Escitalopram |
Escitalopram |
5/10/20 mg |
Cipralex ® |
R 100 million |
Depression |
R 264 million |
SSRI's |
1) First generic to market
2) Originator is fifth leading product in South Africa by value |
| |
|
|
|
|
|
|
|
|
| IMPORTANT REGISTRATIONS 11/2007 |
|
|
|
|
|
|
|
| Finpecia |
Finasteride |
1mg |
Propecia ® |
R 6.4 million |
Prevent androgenetic hairloss |
R 8.9 million |
Hair Loss Preventatives |
1) First generic to market
2) Priced at 70% less than originator
3) Anticipate huge growth in market now that "cosmetic drug" extremely affordable |
| Cipla-Losartan |
Losartan |
25/50/100 mg |
Cozaar ® |
R 15 million |
Hypertension |
R 109 million |
ARB's |
1) First molecule of ARB class to be genericised
2) First to launch both 50mg and 100mg |
| |
|
|
|
|
|
|
|
|
| IMPORTANT REGISTRATIONS 10/2007 |
|
|
|
|
|
|
|
| Cipla-Efavirenz |
Efavirenz |
600mg |
Stocrin ® |
R 92 million |
HIV / AIDS |
R 94.4 million |
Efavirenz |
1) Now first line prescription option for HIV / AIDS
2) FDA and WHO approved
3) Huge tender opportunity |
| Tavaloxx |
Levofloxacin |
250/500/750 mg |
Tavanic ® |
R 80 million |
Bacterial Infections |
R 252 million |
Fluoroquinolones |
1) First and only 750mg launched in South Africa
2) Strong reputation for fluoroquinolone antibiotics eg: Utin, Ciploxx |
| Fincar 5 |
Finasteride |
5mg |
Proscar ® |
R 2.7 million |
Benign Prostatic Hypertrophy |
R 48.8 million |
BPH Products |
1) Second generic in South Africa
2) Nearly 70% less than originator |
| |
|
|
|
|
|
|
|
|
| IMPORTANT REGISTRATIONS 08/2007 |
|
|
|
|
|
|
|
| Cipla-Warfarin |
Warfarin |
1/3/5 mg |
Warfarin |
R 13.4 million |
Prevent blood clots |
R 13.4 million |
Warfarin |
1) We are launching the first and only generic 5mg as well as only 1mg which will
make dosing options much easier |
| Piramax |
Topiramate |
25/100/200 mg |
Topamax ® |
R 25 million |
Epilepsy |
R 264 million |
Antiepileptics |
1) Another new generation antiepileptic added to the already successful Epitec |
| |
|
|
|
|
|
|
|
|
| IMPORTANT REGISTRATIONS 06/2007 |
|
|
|
|
|
|
|
| Cipla-Lamivudine 300 |
Lamivudine |
300mg |
Originator first to market |
First to market |
HIV / AIDS |
R 122 million |
Lamivudine |
1) Allows once daily dosing (instead of twice daily) which should improve
compliance
2) Same pricing as twice daily dosing |
| |
|
|
|
|
|
|
|
|
| ® - Registered Trademarks |
|
|
|
|
|
|
|
Bitmap |
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
